3results about How to "Preserve immunogenicity" patented technology

This invention belongs to the field of biomedical technology, specifically relating to a method for constructing a highly cell-adaptive PEDV GIIc recombinant chimeric virus. Specifically, this invention, based on the PEDV viral S protein determining PEDV's cell adaptability, innovatively elucidates that S2 is the key subunit determining its cell adaptability. On this basis, this invention proposes a scheme that can increase viral titer and thus reduce vaccine production costs when preparing candidate vaccine strains of circulating PEDV strains (especially GIIc). This involves retaining the S2 subunit of the highly cell-adaptive strain and replacing the S1 subunit of the highly cell-adaptive strain with the S1 subunit of the circulating strain, or replacing the S2 subunit of the circulating strain with the S2 subunit of the highly cell-adaptive strain. This scheme can both preserve the immunogenicity of the circulating strain and improve the efficiency of high-titer vaccine production.

The invention discloses application of mesenchymal stem cells derived from an in-vivo stem cell generator. The mesenchymal stem cells are used for preparing drugs for treating inflammatory diseases, especially inflammatory enteritis. According to the method, an artificial controllable inflammatory microenvironment is constructed in vivo through a stem cell generator, so that the immune regulation function of the mesenchymal stem cells is activated, and the activated MSC can effectively promote phenotype conversion from M1 type macrophages to M2 type macrophages, induce T cells to be differentiated into regulatory T cells and inhibit proliferation of the activated T cells. In the treatment of mouse inflammatory bowel disease, the MSC obtained by the method disclosed by the invention obviously improves the survival rate of mice, relieves weight loss, retains a relatively complete crypt structure of a colon part, inhibits infiltration of inflammatory cells to the colon, and rebuilds an inflammatory microenvironment of the colon. The invention provides a brand new method for activating the immunomodulatory function of the mesenchymal stem cells, and a new path is opened up for treating inflammatory and immune diseases.

The application discloses a recombinant 2.1d subtype swine fever E2 protein, a subunit vaccine and application thereof, and belongs to the technical field of genetic engineering. By removing amino acids at positions 344-375 of the 2.1d subtype swine fever E2 protein and retaining amino acids at positions 1-343, the most important antigen epitope of the 2.1d subtype swine fever E2 protein having a protective effect can be retained, the spatial structure of the recombinant 2.1d subtype swine fever E2 protein is basically not affected, and the immunogenicity of the recombinant 2.1d subtype swine fever E2 protein can be retained to the maximum extent. In addition, the recombinant 2.1d subtype swine fever E2 protein can be efficiently expressed in a prokaryotic expression system. Further, by co-expressing a molecular chaperone, the soluble expression level of the recombinant 2.1d subtype swine fever E2 protein can be significantly improved. After the recombinant 2.1d subtype swine fever E2 protein is prepared into a subunit vaccine, the subunit vaccine has good protective efficacy on infection of a 2.1d subtype swine fever virus.